In the randomized trial AML-BFM 93 we compared 60 mg/m 2 /day daunorubicin with 12 mg/m 2 /day idarubicin for 3 days each, combined with cytarabine and etoposide during induction. Results showed a significant better blast cell reduction in the bone marrow on day 15 in patients of the idarubicin arm (25 of 144 = 17% of patients with у5% blasts compared to 46 of 149 = 31% of patients after daunorubicin, P 2 = 0.01). This was, however, mainly seen in high risk patients treated with idarubicin (19% vs 38%, P 2 = 0.007). Cardiotoxicity, WHO grade 1-3 shortening fraction reduction after induction occurred in 6% patients in both arms. Bone marrow toxicity differed slightly with a median recovery time of neutrophils Ͼ500/l of 25 days (daunorubicin) compared to 27 days (idarubicin), P = 0.05. In the total group of patients probabilities of 5 years event-free survival and disease-free survival were similar for patients treated with daunorubicin or idarubicin (49% ± 4% vs 55% ± 4% and 57% ± 4% vs 64% ± 4%, P logrank 0.29 and 0.15, respectively). However, in patients presenting with more than 5% blasts on day 15 there was a trend for a better outcome after treatment with idarubicin (P logrank 0.06). Together with the early effect seen for high risk patients these results indicate a better efficacy of idarubicin than of daunorubicin during induction with a similar rate of toxicity. Leukemia (2001) 15, 348-354. 
Introduction
Therapy results in children and adults with AML improved considerably in the late 1970s and 1980s. Further progress was achieved by a more intensive therapy and bone marrow transplantation. This intensification has become feasible by improved management of infectious complications, a better comprehension of pharmacokinetics and the mechanisms of antileukemic agents such as cytosine arabinoside (Ara-C) and anthracyclines. Next to Ara-C, anthracyclines are the most effective drugs in AML treatment and for many years daunorubicin was the preferred drug in AML. Since several trials in adults compared daunorubicin with idarubicin in induction regimens and achieved high remission rates in patients treated with idarubicin, this drug is increasingly used. [1] [2] [3] In vitro and preclinical studies suggested a possible clinical benefit of idarubicin compared to daunorubicin, showing a faster cellular uptake, increased retention and lower susceptibility to multi-drug resistance in idarubicin. 4, 5 Additional advantages seem to arise from the long plasma half-life of 54 h of its main metabolic idarubicinol, which also shows antileukemic activity in the cerebral spinal fluid. 6 Furthermore, idarubicin has shown fewer cardiotoxic side-effects in several animal models, 4 an important finding regarding the risk of an increased anthracycline-induced cardiomyopathy in chil- dren. 7 Therefore, one of our major objectives was to compare daunorubicin with idarubicin during induction therapy and analyze the efficacy and toxicity of these drugs.
Patients and methods

Eligibility
The entry criteria for study AML-BFM 93 included diagnosis of de novo AML, age between 0 to 17 years, and written informed consent of the patient or parent. Patients with myelosarcoma, secondary AML, myelodysplastic syndrome or Down's syndrome were excluded.
Diagnosis
The initial diagnosis of AML and its subtypes was determined according to the FAB classification. [8] [9] [10] All initial smears were routinely investigated at the University Children's Hospital in Mü nster and were reviewed by a panel of hematologists including one to two external investigators (T Bü chner, H Lö ffler). The diagnoses of M0 and M7 subtypes always required confirmation by immunological methods.
9,10 Day 15 bone marrow aspirates were reviewed centrally.
Treatment
The treatment protocol of study AML-BFM 93 ( Figure 1 ) evolved from study AML-BFM 87. 11 At diagnosis, patients were randomized to receive the 8-day induction with either daunorubicin (ADE: cytosine arabinoside (Ara-C) 100 mg/m 2 /day continuous infusion on days 1 and 2 followed by 30 min infusion every 12 h on days 3-8, daunorubicin 30 mg/m 2 30 min infusion every 12 h on days 3, 4, 5 and etoposide (VP-16) 150 mg/m 2 120 min infusion on days 6, 7, 8) or with idarubicin (AIE: idarubicin 12 mg/m 2 30 min infusion every 24 h, days 3, 4, 5 instead of daunorubicin, Ara-C and VP-16 as in ADE).
After induction, patients were treated according to risk groups. This risk stratification for standard and high risk was based on the initial morphological parameters and the blast cell reduction in the bone marrow (BM) on day 15 (standard risk group: FAB M1/M2 with Auer rods, FAB M3 and FAB M4eo with р5% blasts in the bone marrow on day 15; high risk group: all others). 12 Thus, patients, who had been allocated initially to standard risk by morphological parameters were shifted to the high risk group when presenting with Ͼ5% blasts in the BM on day 15. Patients with FAB M3 were always treated as standard risk, regardless of their blast count on day 15 (these patients additionally received ATRA during Treatment schedule of study AML-BFM 93.
induction). There was a high correlation between favorable karyotypes and the standard risk group.
12
High risk patients were randomized to receive either HAM (high-dose Ara-C 3 g/m 2 every 12 h for 3 days and mitoxantrone 10 mg/m 2 on days 4 and 5) followed by consolidation (arm HR1) or consolidation followed by HAM (arm HR2 Intensification for all patients was given with one block of high-dose Ara-C and VP-16. This was followed by cranial irradiation with 18 Gy (standard dose in children у3 years) and maintenance therapy with daily thioguanine 40 mg/m 2 orally and Ara-C 40 mg/m 2 s.c. × 4 days monthly for a total duration of 18 months. Allogeneic bone marrow transplantation (BMT) was recommended for children of the high risk group in first CR, if a HLA-identical sibling donor was available.
Definition and statistics
Complete remission (CR) was defined according to the CALGB criteria 13 and had to be achieved by the end of intensification treatment. Early death (ED) patients were those dying before or within the first 6 weeks of treatment.
Permuted blocks were used for both randomizations. The planned sample size was 440 for the randomization of AIE vs ADE. The first endpoint to measure efficacy was early response, defined by blast cell count in day 15 bone marrow. The power to detect a decrease from 32% patients with more than 5% bone marrow blasts on day 15 (result of study AML-BFM 87) to 20% was 80%. Secondary endpoints were rate of CR and event-free survival (EFS). The blast cell clearance in Leukemia the bone marrow on day 15 was used as the main indicator for the efficacy of induction therapy because different therapy options or modifications in post-remission treatment will influence outcome.
EFS was calculated from date of diagnosis to last follow-up or to the first event (failure to achieve remission, early death, resistant leukemia, relapse or death of any cause). For patients who failed to achieve remission EFS was set to zero. Survival was calculated from date of diagnosis to death of any cause or last follow-up. Disease-free survival (DFS) of patients achieving remission was calculated from date of remission to first event (relapse, death of any cause).
Toxicities were measured according to the NCI common toxicity criteria.
14 Univariate analysis was conducted by the Wilcoxon test for quantitative variables and Fisher exact test for qualitative variables. When frequencies were sufficiently large the 2 statistic was used. For testing trends in frequency tables the CochranArmitage test was applied. Analysis of efficacy data was performed according to the intent-to-treat principle. Toxicity data were evaluated for treatment groups. Computations were performed using SAS (Statistical Analysis System Version 6.12, SAS Institute, Cary, NC, USA).
Patient characteristics
From January 1993 to December 1997, 435 patients were enrolled in study AML-BFM 93 (As of 31 December 1997 randomisation 1 was closed to patient accrual whereas randomization 2 continued for 6 months.) Follow-up was as of January 2000.
Of the 435 patients 358 (82%) were randomized to ADE or AIE (Table 1) . Seventy-seven patients were not randomized for the following reasons: 26 patients mainly due to initial complications by leukostasis or hemorrhage leading to early death; in 51 children the therapy was selected by parents or physicians. Two patients allocated to ADE received AIE and four children allocated to AIE received ADE. However, for the intent-to-treat analysis these patients remained in their randomized arm.
The presenting features of the total group of patients, the non-randomized patients and the randomized groups are shown in Table 1 . Non-randomized patients had a younger median age than randomized children (P Wilcoxon 0.02) and showed a trend towards a higher initial white blood cell count (P Wilcoxon 0.07). The FAB distribution was similar between non-randomized and randomized patients and is shown for the randomized groups in Figure 2 (P 2 = 0.38). When comparing the randomized groups ADE and AIE in regard to the distribution of initial patient data no clinically important differences were found.
Results
Overall outcome
In study AML-BFM 93, 356 of 435 (82%) patients achieved remission. The estimated probabilities for 5-year survival, EFS and DFS were 59%, s.e. 3%, 51%, s.e. 3% and 63%, s.e. 3%, respectively.
Results of the randomized groups treated with ADE or AIE
For the analysis of treatment effect on blast cell reduction, patients with FAB M3 were excluded as blast count on day 15 was not of prognostic significance for this group.
Figure 2
FAB distribution in the randomized groups.
More patients in the AIE group (119 of 144 = 83%) achieved a blast cell reduction with р5% blasts on day 15 than in the ADE group, (103 of 149 = 69%, P 2 = 0.01, see Table 2 ). According to the final risk group stratification by day 15 (see patients and methods) eight of 76 (10%) AIE patients and 14 of 76 (18%) ADE patients (P = 0.18) were shifted from standard risk to high risk group. The better blast cell reduction on day 15 was seen in high risk patients (defined by initial morphological data only) treated with idarubicin (Table 2) . In this group, 71 of 88 (81%) patients had less than 5% blasts on day 15 compared with 52 of 84 (62%) patients treated with daunorubicin (P = 0.06). This difference was not seen in standard risk patients.
The incidence of early death was similar in both arms with five patients in the ADE and nine patients in the AIE arm (P Fisher test 0.41). It should be noted that three early deaths in the latter group occurred in patients with hyperleukocytosis of Ͼ200 000/l and that one patient died soon after HAM treatment. Another patient succumbed to his disease shortly after randomization to AIE, without having received idarubicin.
Overall results in randomized patients showed no significant differences when comparing the CR rate (Table 3) , time to achieve CR (median: AIE 56 days, ADE 65 days, P Wilcoxon test = 0.14), pEFS (Figure 3 ), pDFS or P survival. However, CR rates were different between standard and high risk patients treated with ADE (92% vs 83%, P = 0.05) but similar in standard and high risk patients treated with AIE (88% vs 86%, P = 0.61). In addition, significantly different results were seen in patients with р5% vs Ͼ5% blasts on day 15 treated with ADE (pEFS: 0.58, s.e. 0.05 vs 0.33, s.e. 0.07, P logrank = 0.003), and more similar results in patients treated with AIE (pEFS: 0.59, s.e. 0.05 vs 0.49, s.e. 0.10, P logrank = 0.58).
Toxicity
There was a trend to a higher infection rate in the AIE group compared to the ADE group (P trend = 0.016, Table 4 ). Mucositis was severe (уgrade 2 toxicity) in 10 of 27 AIE patients compared to two of 11 ADE patients (P Fisher = 0.45). A similar rate of cardiotoxicity (grade 1-3 shortening fraction reduction) was seen in ADE and AIE (eight and seven patients (6%), respectively). Other non-hematological toxicities were in the same range in both groups (Table 4) .
Hematological toxicity measured by aplasia from induction 
Figure 3
Estimated probability for event-free survival for patients randomized for ADE and AIE in study AML-BFM 93. Slash indicates last patient of the group. until neutrophil recovery to 500/l revealed a 2 day longer recovery time for patients in the AIE group compared to the ADE group. There was no significant difference in the platelet recovery time between the two arms ( Table 4) .
The time to reach the nadir of the white blood cell count Leukemia (WBC) was a median of 14 days in ADE compared to 15 days in AIE (P Wilcoxon test = 0.01), and was identical in both groups for platelets (15 days).
Results by second randomization HR 1 vs HR 2
One hundred and ninety-four patients were randomized in either HR1 (n = 95) or HR2 (n = 99), (Figure 1) . Overall results were similar in both arms regarding response and relapse rate.
Tests for interaction in a Cox regression model showed a worse outcome only in patients randomized to ADE followed by HR2 (RR 1.8, P = 0.04). Non-hematological toxicity was also similar.
Discussion
One aim of study AML-BFM 93 was the evaluation of the efficacy of idarubicin compared to daunorubicin in AML induction therapy in children. A systematic overview of randomized trials comparing induction therapies containing idarubicin or daunorubicin has been conducted by the British AML collaborative group. 15 Induction failures were similar with both drugs, and although a higher CR rate and lower relapse rate was seen in patients treated with idarubicin, slightly more patients died in remission, translating to a non-significant benefit in DFS. However, all these trials lacked an equivalent dose comparison (3 × 12 mg/m 2 idarubicin with 3 × 45-50 mg/m 2 daunorubicin). 16 The definition of equivalence may be equal toxicity or equal efficacy against the disease.
15 Our dose relation of 1:5 (3 × 12 mg/m 2 idarubicin vs 3 × 60 mg/m 2 daunorubicin) seems to provide a more appropriate basis for comparison, which was acknowledged by the AML Collaborative Group in 1998. 15 These doses showed slightly higher toxicity in our study. Thus, for equitoxicity, an even higher idarubicin/daunorubicin ratio might be worth considering.
Early response to therapy evaluated by day 15 marrow was an independent prognostic factor in studies AML-BFM 83 and 87. 12 Recently, this was supported by data of trials in childhood acute lymphoblastic leukemia. 17, 18 The most important result comparing idarubicin and daunorubicin during induction in our study was the blast cell reduction on day 15 with only 17% of AIE patients presenting with Ͼ5% blasts compared to 31% after ADE. This was in line with our results of study AML BFM 87, where all patients were treated with ADE and where 31% of the patients presented Ͼ5% blasts on day 15.
12 However, the difference in the number of patients with Ͼ5% blasts on day 15 after AIE compared to ADE was restricted to the (morphologically defined) high risk patients (P = 0.007) and was not significant in standard risk patients. This seems to indicate that an induction with daunorubicin may be already sufficient for standard risk patients, but not for high risk patients and that mainly high risk patients benefit from the treatment with idarubicin.
In the group of patients with Ͻ5% blasts on day 15, no difference between ADE and AIE was seen in the randomized groups for overall survival and for pEFS (0.58, s.e. 0.05 vs 0.58, s.e. 0.05, P = 0.99). This may be due to the early intensification courses in our study which interact with the advantage of the better blast cell reduction after idarubicin. However, a tendency for an improved outcome in patients treated with AIE could be demonstrated in patients with Ͼ5% blasts on day 15 (0.32, s.e. 0.07 vs 0.55, s.e. 0.10, P = 0.06, Figure 4 ). Together with the early effect found in high risk patients this indicates a better efficacy of idarubicin compared to daunorubicin mainly for unfavorable patient groups. The
Figure 4
Estimated probability for event-free survival for patients with Ͼ5% blasts on day 15 randomized for ADE and AIE in study AML-BFM 93 (FAB M3 excluded). Slash indicates last patient of the group.
prognostic factor 'blast cell reduction on day 15' which was evaluated as a risk factor for achieving remission and for pEFS after ADE induction in studies AML-BFM 83 and 87 (P 2 Ͻ0.0001 and P logrank = 0.0001, respectively) 12 lost its significance after AIE induction (Table 2) . Only patients treated with ADE and more than 5% blasts on day 15 had lower CR rates compared with ADE treated patients and р5% blasts on day 15.
Considering the reported trials of idarubicin and daunorubicin in adults, there were non-significant differences in the early death rate. However, after 40 days, the number of patients with induction failures was significantly higher in the daunorubicin group. 15 Most of the later deaths had to be related to resistant disease. In our study the early death rate was low and in both treatment arms an equal CR rate was achieved. Time to achieve CR was a median of 9 days shorter after AIE (P = 0.14).
However, therapy-induced toxicity, especially hematological toxicity (duration of aplasia) seemed to be slightly more severe with idarubicin, which supports the finding in adults studies. 19 Non-hematological complications were in the same range. No significant differences were seen in early cardiotoxicity, however, data on late cardiotoxicity (after 5 to 10 years) have to be awaited.
In conclusion, AML induction treatment with AIE resulted in an improved blast cell clearance in children without clinically relevant increased toxicity when compared to the daunorubicin-treated patients. This appears to be beneficial mainly for high risk patients. In the ongoing study AML BFM 98 daunorubicin was omitted and replaced by idarubicin.
